Virbac: Stifel lowers target price
(CercleFinance.com) - Stifel confirms its 'hold' rating on Virbac shares, with a target price lowered from E420 to E380.
Virbac's share price has suffered since its impressive H1 2024 publication, although recent Q3 2024 results are in line with the group's solid annual targets of 7-9% organic growth, the broker points out.
The analyst believes Virbac should achieve +20% EPS growth in 2024, thanks to a low comparison basis, followed by more normalised growth of +10% in 2025, and then EPS growth above 10% beyond 2025.
In the near term we have concerns about the economic environment, Stifel says. Overall, we think it would be premature to become more optimistic just yet, although Virbac should remain on investors' radar, it concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Virbac's share price has suffered since its impressive H1 2024 publication, although recent Q3 2024 results are in line with the group's solid annual targets of 7-9% organic growth, the broker points out.
The analyst believes Virbac should achieve +20% EPS growth in 2024, thanks to a low comparison basis, followed by more normalised growth of +10% in 2025, and then EPS growth above 10% beyond 2025.
In the near term we have concerns about the economic environment, Stifel says. Overall, we think it would be premature to become more optimistic just yet, although Virbac should remain on investors' radar, it concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.